|
|
|
Volumn 21, Issue 6, 2010, Pages 338-341
|
|
Opinions in hypertension management - ARBs and risk of cancer: International and South African expert comment
a
c
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOTENSIN RECEPTOR ANTAGONIST;
CANDESARTAN;
CAPTOPRIL;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
LOSARTAN;
PLACEBO;
RAMIPRIL;
TELMISARTAN;
VALSARTAN;
ANGIOTENSIN 1 RECEPTOR ANTAGONIST;
ANTIHYPERTENSIVE AGENT;
ACUTE HEART INFARCTION;
BREAST CANCER;
CANCER MORTALITY;
CANCER RISK;
CARDIOVASCULAR DISEASE;
CLINICAL TRIAL (TOPIC);
DIABETES MELLITUS;
DRUG SAFETY;
HEART FAILURE;
HUMAN;
HYPERTENSION;
LUNG CANCER;
META ANALYSIS (TOPIC);
NEOPLASM;
NOTE;
PROSTATE CANCER;
SOLID TUMOR;
SOUTH AFRICA;
ARTICLE;
CHEMICALLY INDUCED DISORDER;
EVIDENCE BASED MEDICINE;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
RISK ASSESSMENT;
RISK FACTOR;
ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS;
ANTIHYPERTENSIVE AGENTS;
EVIDENCE-BASED MEDICINE;
HUMANS;
HYPERTENSION;
META-ANALYSIS AS TOPIC;
NEOPLASMS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RISK ASSESSMENT;
RISK FACTORS;
|
|
EID: 78650827387
PISSN: 19951892
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (2)
|
|
References (2)
|
